Skip to main content

Tau PET Imaging Using 18F-AV-1451


This study will evaluate a new radioactive compound, 18F-AV-1451, in identifying tau tangles in positron emission tomography (PET) scans. Tau is a protein that accumulates abnormally in the brains of people with Alzheimer's disease and other neurodegenerative disorders.

Minimum Age Maximum Age Gender Healthy Volunteers
65 Years N/A All No
May 2016
November 2021

  • Able to undergo a lumbar puncture or has previously had one
  • Able to undergo PET and magnetic resonance imaging scans of the brain
  • Negative urine pregnancy test 24 hours before drug administration

  • Any condition that could increase participant's risk, limit ability to undergo the procedures, or interfere with data collection and analysis
  • History of Torsade de Pointes, a rare heart arrhythmia, or use of medications that prolong the QT interval
  • Known hypersensitivity to the compound T807 or its other ingredients
  • Severe claustrophobia
  • Pregnant or breastfeeding

In this Phase II study, participants will receive an intravenous injection of the compound 18F-AV-1451 and undergo a PET scan to show measurement of tau deposition. Participants also may undergo optional PET imaging with another compound to measure glucose use in the brain and may volunteer for follow-up T807-PET imaging at least 2 years after the initial scan. Researchers will evaluate  changes in T807-PET measures over time, as well as the association between levels of tau and changes in cerebrospinal fluid biomarkers and cognitive function.

Name City State Zip Status Primary Contact
Washington University School of Medicine
Saint Louis Missouri 63110 Recruiting Kelley Jackson

Washington University School of Medicine

Name Role Affiliation
Tammie Benzinger, PhD Principal Investigator Washington University School of Medicine

Name Phone Email
Theresa Butler 314-362-1558


Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD in Humans